CHMA News and Press, Chiasma Inc. From 03/17/20

Image source: The Motley Fool. Chiasma Inc   (NASDAQ: CHMA) Q4 2019 Earnings Call Mar 16, 2020 , 5:00 p.m. ET Operator Continue reading

Chiasma, Inc. (CHMA) Q4 2019 Earnings Conference Call March 16, 2020 05:00 p.m. ET Company Representatives Raj Kannan - Chief Executive Officer Bill Ludlam - Senior VP of Clinical Development & Medical Affairs Mark Fitzpatrick - President Dawn Schottlandt - VP, IR & Cor...

Chiasma (NASDAQ: CHMA ): Q4 GAAP EPS of -$0.29 misses by $0.06 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

MYCAPSSA ® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clini...

NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on&#...

The FDA accepts for review Chiasma's ( CHMA +1.3% ) resubmitted marketing application for Mycapssa (octreotide) for the maintenance treatment of adults with acromegaly. More news on: Chiasma, Inc., Healthcare stocks news, Read more ...

FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chr...

Thinly traded micro cap Chiasma (NASDAQ: CHMA ) perks up  4%  premarket on light volume on the heels of its corporate update and 2020 expected milestones. More news on: Chiasma, Inc., Healthcare stocks news, Stocks on the move, Read more ...

MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA ® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA ® MPOWERED Phase 3 results on track for the fourth quarter of 2020 NEEDHAM, Mass., Jan. 10, 20...

NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology In...